Toujeo (Long-acting Recombinant Human Insulin Analogue) / Sanofi - LARVOL DELTA

INTENSIFICATION WITH INSULIN GLARGINE 300 U/ML (GLA-300) IN PEOPLE WITH TYPE 2 DIABETES (PWT2D) RECEIVING TIRZEPATIDE THERAPY: DELIVER-T (ATTD 2026) - "In insulin-naïve PwT2D who had uncontrolled HbA1c with tirzepatide, significant reductions in HbA1c and improvements in the percentage of PwT2D reaching HbA1c target of ≤7% were observed with Gla-300, a second-generation basal insulin. Funded by Sanofi. Full manuscript published in Diabetes Therapy."

Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

REAL-WORLD RETROSPECTIVE COHORT STUDY COMPARITIVE IMPACT OF EARLY VS LATE GLA-300 INTENSIFICATION AFTER GLP-1RA/SGLT-2I ± OAD IN INSULIN-NAÏVE T2D (RESTORE EARLY) (ATTD 2026) - "The results of RESTORE-EARLY will enhance understanding of the clinical value of timely basal insulin intensification with Gla-300, supporting evidence-based strategies to improve glycemic outcomes in real-world T2D management."

Real-world • Real-world evidence • Retrospective data • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

SEVERE INSULIN RESISTANCE IN TYPE 2 DIABETES SUCCESSFULLY MANAGED WITH MEDTRONIC 780G CLOSED-LOOP SYSTEM: A CASE REPORT (ATTD 2026) - "Her regimen included high-dose rapid-acting insulin lispro U-200, long-acting insulin glargine U-300 (Toujeo), maximum-dose metformin (1000 mg BID), and once-weekly semaglutide (Ozempic) at 1.2 mg. This case highlights the potential role of advanced diabetes technologies such as the Medtronic 780G closed-loop insulin delivery system in managing extreme insulin resistance in type 2 diabetes. Even in cases with longstanding hyperglycemia and high insulin requirements, automated insulin delivery can significantly improve glycemic control and reduce insulin needs. This supports broader consideration of insulin pump therapy in selected patients with refractory type 2 diabetes."

Case report • Clinical • Acromegaly • Cushing’s Disease • Diabetes • Endocrine Disorders • Immunology • Metabolic Disorders • Type 2 Diabetes Mellitus

NN1436-7727: A Research Study to See How Well Weekly Insulin Icodec Maintains Blood Sugar Levels Compared to Daily Basal Insulins in Adults with Type 2 Diabetes (clinicaltrialsregister.eu) - P4 | N=204 | Not yet recruiting | Sponsor: Novo Nordisk A/S

New P4 trial • Real-world evidence • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Cost-utility of once-weekly insulin icodec versus once-daily basal insulins for type 2 diabetes in China. (PubMed, Diabetes Obes Metab) - "Once-weekly icodec represents a cost-effective and clinically beneficial alternative to once-daily basal insulin analogues for Chinese adults with type 2 diabetes within the current reimbursement framework."

HEOR • Journal • Cardiovascular • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes (clinicaltrials.gov) - P4 | N=324 | Not yet recruiting | Sponsor: Yanbing Li | Initiation date: Oct 2025 ➔ Mar 2026

Trial initiation date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Insulins for type 2 diabetes. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Comparison chart: Some available insulins for type 2 diabetes. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Efficacy and safety of switching basal insulin to insulin glargine 300 U/mL in individuals with inadequately controlled type 2 diabetes on advanced insulin therapies: The Toujeo-Neo T2DM study. (PubMed, Diabetes Obes Metab) - "Switching BI to Gla-300 from a BOTplus or MDI regimen with prior insulin Gla-100, IDeg, IDet, or NPH improved glycaemic control in participants with inadequately controlled T2DM over 12 months without increasing hypoglycaemia risk or weight gain."

Journal • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Effects of age and disease duration on the glycaemic outcomes and safety of insulin glargine 300 U/mL in people with type 2 diabetes in China: A post-hoc analysis of the INITIATION study. (PubMed, Diabetes Obes Metab) - "Gla-300 improved glycaemic control with a low risk of hypoglycaemia in Chinese people with T2D across all ages and disease durations, including older individuals and those with long-standing diabetes."

Journal • Retrospective data • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Comparative Effectiveness of Switching From First-Generation Basal Insulins to Either Glargine 300 U/mL or Degludec 100 U/mL in Children and Adolescents With Type 1 Diabetes: Results From the ISPED CARD Clinical Registry. (PubMed, Pediatr Diabetes) - "To assess the real-world effectiveness of switching from first-generation basal insulins (1BIs) to either glargine U300 (Gla-300) or degludec U100 (Deg-100) in children and adolescents with type 1 diabetes (T1D), using data from the Italian ISPED CARD clinical registry. Although both insulins showed comparable effectiveness, differences in titration patterns highlight the need for individualized treatment strategies and improved clinician education in insulin optimization. Safety outcomes, particularly hypoglycemia, could not be assessed."

Clinical • HEOR • Journal • Observational data • Retrospective data • Diabetes • Hypoglycemia • Metabolic Disorders • Pediatrics • Type 1 Diabetes Mellitus

Real-World Effectiveness of Insulin Glargine 300 U/ml in People with Type 2 Diabetes Previously Treated with Tirzepatide: The DELIVER-T Study. (PubMed, Diabetes Ther) - "In insulin-naïve people with T2D who had suboptimal HbA1c with tirzepatide, significant reductions in HbA1c and improvements in the percentage of people reaching HbA1c target of < 7.0% were observed with Gla-300. Infographic and video abstract available for this article. Please follow the digital features link under the abstract. A video abstract of the Deliver-T study, which evaluated glycaemic control in people with T2D previously treated with tirzepatide and newly intensified with insulin glargine 300 U/mL (Gla-300)."

Journal • Real-world evidence • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Efficiency of Gla-300 versus Gla-100 Across Age Groups in People Living with Type 2 Diabetes in France: A Post Hoc Analysis of an Observational Longitudinal Study. (PubMed, Adv Ther) - "This EF-BI post hoc analysis found that Gla-300 was associated with lower overall costs, better persistence, and fewer insulin-related acute events compared to Gla-100 in several age subgroups in people with T2D in France. Further investigations are needed to confirm these results, including glycemic control and comparison with other second-generation basal insulins."

Journal • Observational data • Retrospective data • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Derived time-in-ranges in insulin-naive older adults with type 2 diabetes treated with insulin glargine 300 U/mL vs degludec 100 U/mL: a BRIGHT trial post-hoc analysis (EASD 2025) - P4 | "In PWT2D, Gla-300 and IDeg-100 improved dTIR, reduced dTAR, without increasing dTBR in older participants (≥70 years)."

Clinical • Retrospective data • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Differences in the expression of insulin pathway genes according to the basal insulin analogue treatment used in the INEOX study (EASD 2025) - P4 | "So, we tried to evaluate potential differences in the gene expression of the insulin signaling pathway in leukocytes from adults with type 1 diabetes mellitus (T1DM), depending on the treatment with different long-acting basal insulin analogs, using data from the INEOX study.Materials and INEOX is a 24-week controlled clinical trial comparing two groups of T1DM patients (diagnosed over 2 years ago, treated for more than 1 year with rapid-acting insulin analogs, and with HbA1c above 10%) who were randomly assigned to treatment with Glargine U300 (Gla300) or Degludec U100 (Deg100). Our results suggest the potential differential regulation of the insulin pathway gene SOCS2 in adult women with T1DM treated with different second-generation long-acting basal insulin analogs, as differences were observed depending on the insulin analog used."

Diabetes • Hypoglycemia • Metabolic Disorders • Type 1 Diabetes Mellitus • GAPDH • SOCS2

Cost effectiveness of basal insulin across age groups in France: a post-hoc analysis of an observational longitudinal study (EASD 2025) - "The results of this EF-BI post-hoc analysis suggests that overall costs, treatment adherence, and hospitalized acute events possibly related to insulin therapy favor Gla-300 over Gla-100 in the T2DM population in France, regardless of age."

Cost effectiveness • HEOR • Longitudinal study • Observational data • Retrospective data • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Aging with type 1 diabetes: a perspective on "octagenarians" living with type 1 diabetes in Italy (EASD 2025) - "Among patients treated with the conventional basal-bolus insulin regimen, most (76.5%) were treated with second-generation basal insulin (glargine U300 or degludec). The most used rapid insulin analogues were lispro (44%), aspart (32.4%), glulisine (10%), and faster aspart (11.9%)... Many people with type 1 diabetes have aged, becoming 'octogenarians' by being regularly followed up in Italian diabetes centers. The overall quality of care for patients regularly followed up has resulted in a lower-than-expected burden of end-stage renal disease, visual loss, and diabetic foot. Management of CV risk factors could be improved."

Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

Effectiveness and Safety of Insulin Glargine 300 U/ml in High-Risk Subgroups (Renal Impairment and Older Age ≥ 70 years) of Insulin-Naïve People with Type 2 Diabetes: A Post hoc Analysis of Real-World ATOS Study. (PubMed, Diabetes Ther) - P=N/A | "In a real-world setting, the initiation of Gla-300 in insulin-naïve PwT2D uncontrolled on OADs resulted in improved glycemic control with a low incidence of hypoglycemia and minimal weight change in participants with a history of RI and in older participants."

Journal • Real-world evidence • Retrospective data • Diabetes • Hypoglycemia • Metabolic Disorders • Renal Disease • Type 2 Diabetes Mellitus

Effectiveness and safety of early insulin glargine U100 and glargine U300 administration in the management of diabetic ketoacidosis in adults with type 1 diabetes mellitus: A randomized clinical trial. (PubMed, Endocr Pract) - "Early combination iGlar U100 or iGlar U300 with intravenous insulin infusion was associated with faster resolution of DKA and reduced total insulin requirements without increasing the risk of hypoglycemia or hypokalemia. Both iGlar U100 and U300 displayed similar safety and efficacy."

Clinical • Journal • Diabetes • Hypoglycemia • Metabolic Disorders • Type 1 Diabetes Mellitus

Real-World Evidence of Health Care Resource Use and Clinical Outcomes in People with Type 2 Diabetes and Impaired Renal Function Switching from First- to Second-Generation Basal Insulins in England (ADA 2025) - "To understand the health care resource use (HCRU) and clinical outcomes in patients with type 2 diabetes mellitus (T2DM) and decreased renal function (estimated glomerular filtration rate [eGFR]<60 ml/min/1.73 m2) who switched from a Gen1 BI to a Gen2 BI. In this retrospective, observational study in England, adults with T2DM who initiated treatment with a Gen1 BI (e.g., glargine 100 U/mL, detemir) and switched to a Gen2 BI (glargine 300 U/mL [Gla-300] or degludec [IDeg-100]) (index date) between 01/07/2014 and 31/03/2021 were analyzed using the Clinical Practice Research Datalink (CPRD) Aurum linked to Hospital Episode Statistics... This real-world study demonstrated that patients with T2DM and impaired renal function who switched to Gla-300 from Gen1 BI had lower HCRU among those treated with a second-generation BI."

Clinical • Clinical data • HEOR • Late-breaking abstract • Real-world • Real-world evidence • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus • GEN1

CGM-Based Real-World Data on the Transition from Glargine U100 to U300 in Children and Adolescents with Type 1 Diabetes. (PubMed, Horm Metab Res) - "The study provides real-world, CGM-based evidence suggesting that glargine U300 offers a safer, more stable option for managing T1D in children, particularly in reducing hypoglycemia. These findings highlight glargine U300's potential advantages in glycemic stability, supporting its use in pediatric diabetes care."

Journal • Real-world evidence • Diabetes • Hypoglycemia • Metabolic Disorders • Pediatrics • Type 1 Diabetes Mellitus

The impact of Insulin Degludec and Liraglutide Injection on clinical remission in patients with early - stage type 2 diabetes (ChiCTR) - P4 | N=600 | Recruiting | Sponsor: The First Affiliated Hospital of Guangxi University of Traditional Chinese Medicine; The First Affiliated Hospital of Guangxi University of Traditiona

New P4 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Insights on Hospitalisations from the Phase 3a ONWARDS 1-6 Trials of Once-Weekly Insulin Icodec. (PubMed, Diabetes Ther) - P3 | "Similar numbers of hospitalisations were reported in both treatment arms. Icodec treatment was continued during hospitalisation in most participants and did not appear to have an impact on glycaemic management or hypoglycaemia. This analysis suggests that once-weekly icodec could be managed in a similar way to once-daily basal insulin analogues during hospitalisation."

Journal • P3 data • Diabetes • Hypoglycemia • Metabolic Disorders • Severe Hypoglycemia • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus

Remote And Decentralised Innovative Approaches to Clinical Trials (RADIAL) (clinicaltrials.gov) - P4 | N=107 | Completed | Sponsor: Mira Zuidgeest | Active, not recruiting ➔ Completed | Trial completion date: Nov 2025 ➔ Jan 2025

Trial completion • Trial completion date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Healthcare utilization and costs in adults with type 2 diabetes treated with first or second-generation basal insulins in England. (PubMed, BMJ Open Diabetes Res Care) - "These findings suggest that Gla-300 may offer clinical and economic benefits by reducing hypoglycemia incidents and lowering healthcare costs compared with first-generation BI."

HEOR • Journal • Observational data • Retrospective data • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus